Slow magnetic relaxation in high-coordinate Co(II) and Fe(II) compounds bearing neutral tetradentate ligands

The first-row transition metal compounds, [M^II(L1)₂](ClO₄)₂ (M = Ni (1); Co (2)), have been prepared by treatment of a neutral tetradentate ligand (L1 = N²,N⁹-dibutyl-1,10-phenanthroline-2,9-dicarboxamide) with metal perchlorate salts in MeOH. Both compounds have been structurally characterized by X-ray crystallography and it was found that the coordination numbers are 6 and 7, respectively. The reaction of 6,6'-bis(2-^tbutyl-tetrazol-5-yl)-2,2'-bipyridine (L2) with hydrated Fe^II(ClO₄)₂ afforded a 8-coordinate Fe(II) compound, [Fe^II(L2)₂](ClO₄)₂ (3); however its reaction with hydrated Co^II(ClO₄)₂ resulted in 6-coordinate [Co^II(L2)₂](ClO₄)₂. It is interesting to observe field-induced slow magnetic relaxation in the 7-coordinate Co(II) compound 2 and 8-coordinate Fe(II) compound 3, which further supports the validity of designing high coordination number compounds as single-molecule magnets. Direct current magnetic studies demonstrate that 2 has a very large positive D value (56.2 cm^-1) and a small E value (0.66 cm^-1), indicating easy plane magnetic anisotropy. Consistent with the larger D value, an effective spin-reversal barrier of U_eff = 100 K (71.4 cm^-1) is obtained, which is the highest value reported for 7-coordinate Co(II) complexes with a pentagonal bipyramidal geometry. In contrast, 8-coordinate Fe(II) compound 3 exhibits uniaxial magnetic anisotropy.

Slow magnetic relaxation in a homo dinuclear Dy(iii) complex in a pentagonal bipyramidal geometry

We hereby report a dinuclear Dy(iii) complex, [Dy(LH₃)Cl₂]₂·2Et₂O (1) (LH₄ = 2,3-dihydroxybenzylidene)-2-(hydroxyimino)propanehydrazide where both the metal centres are in a pentagonal bipyramidal (PBP) geometry with the axial positions being occupied by negatively charged Cl^- ions. The complex as well as it's 10% diluted analogue (1₁₀) do not show zero-field SMM behaviour. However, in the presence of small optimum dc fields the slow relaxation of magnetization was displayed. The effective energy barrier for 1₁₀ at 800 Oe of applied field was extracted as 83(17) K with τ₀ = 2(4) × 10^-12 s. Through a combined experimental and ab initio electronic structure calculations studies we have thoroughly analysed the role of the ligand field around the Dy(iii), present in pentagonal bipyramidal geometry, in contributing to the slow relaxation of magnetization.

Field-induced slow magnetic relaxation in low-spin S = 1/2 mononuclear osmium(v) complexes

Photochemical reactions of (PPh4)[OsVI(N)(L)(CN)3] (NO2-OsN) with piperidine and pyrrolidine afforded two osmium(v) hydrazido compounds, (PPh4)[OsV(L)(CN)3(NNC5H10)] ([PPh4]1) and (PPh4)[OsV(L)(CN)3(NNC4H8)] ([PPh4]2), respectively. Their structures consist of isolated, mononuclear distorted octahedral osmium anions that are well-separated from each other by PPh4+. Their low spin S = 1/2 and L = 1 ground state was confirmed by magnetometry and DFT calculations. Interestingly, both compounds exhibit slow magnetic relaxation under a bias dc-field. These osmium(v) complexes are potentially useful building-blocks for the construction of molecule-based architectures with interesting magnetic properties. In contrast, the structurally related (PPh4)[OsIII(L)(CN)3(NH3)] ([PPh4]3), which also has a low-spin S = 1/2 ground state but with a different electronic configuration (5d5), does not exhibit slow magnetic relaxation, due to the absence of any orbital moment (L = 0). Furthermore, the structurally different osmium(v) hydrazido compound reported by Meyer, [OsV(tpy)(Cl)2(NNC5H10)](PF6) (4[PF6]), also does not exhibit slow magnetic relaxation due possibly to a change in magnetic anisotropy from axial for [PPh4]1 and [PPh4]2 to planar.

Design of Rhenium Compounds in Targeted Anticancer Therapeutics

Background:

Many rhenium (Re) complexes with potential anticancer properties have been synthesized in the recent years with the aim to overcome the clinical limitations of platinum agents. Re(I) tricarbonyl complexes are the most common but Re compounds with higher oxidation states have also been investigated, as well as hetero-metallic complexes and Re-loaded self-assembling devices. Many of these compounds display promising cytotoxic and phototoxic properties against malignant cells but all Re compounds are still at the stage of preclinical studies.

Methods:

The present review focused on the rhenium based cancer drugs that were in preclinical and clinical trials were examined critically. The detailed targeted interactions and experimental evidences of Re compounds reported by the patentable and non-patentable research findings used to write this review.

Results:

In the present review, we described the most recent and promising rhenium compounds focusing on their potential mechanism of action including, phototoxicity, DNA binding, mitochondrial effects, oxidative stress regulation or enzyme inhibition. Many ligands have been described that modulating the lipophilicity, the luminescent properties, the cellular uptake, the biodistribution, and the cytotoxicity, the pharmacological and toxicological profile.

Conclusion:

Re-based anticancer drugs can also be used in targeted therapies by coupling to a variety of biologically relevant targeting molecules. On the other hand, combination with conventional cytotoxic molecules, such as doxorubicin, allowed to take into profit the targeting properties of Re for example toward mitochondria. Through the example of the diseleno-Re complex, we showed that the main target could be the oxidative status, with a down-stream regulation of signaling pathways, and further on selective cell death of cancer cells versus normal cells.